RCT of Tocilizumab for Anti-MDA5+DM — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RCT of Tocilizumab for Anti-MDA5+DM — Stella

Home/Dermatomyositis/

View on ClinicalTrials.gov

Recruiting

Back to Dermatomyositis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Key details

Sponsor

Peking Union Medical College Hospital

Enrollment target

~110 participants

Started

November 2025

Primary completion

October 2026

Age range

18 Years – 65 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.